Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 1,060,000 shares, a decline of 23.7% from the February 13th total of 1,390,000 shares. Approximately 13.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 92,200 shares, the days-to-cover ratio is presently 11.5 days.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KPTI. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. HC Wainwright raised their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Stock Down 2.1 %

NASDAQ:KPTI traded down $0.12 during trading hours on Wednesday, hitting $5.71. 10,683 shares of the stock traded hands, compared to its average volume of 73,917. The company has a market cap of $48.08 million, a price-to-earnings ratio of -5.58 and a beta of 0.11. Karyopharm Therapeutics has a 1 year low of $5.56 and a 1 year high of $24.75. The stock has a 50 day moving average price of $8.93 and a 200 day moving average price of $10.79.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.90) by $0.30. The business had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. Equities analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of large investors have recently made changes to their positions in KPTI. Geode Capital Management LLC raised its holdings in Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after purchasing an additional 43,856 shares in the last quarter. FMR LLC increased its holdings in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Karyopharm Therapeutics by 23.5% during the fourth quarter. Northern Trust Corp now owns 283,729 shares of the company’s stock valued at $192,000 after acquiring an additional 54,061 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after acquiring an additional 543,556 shares in the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at about $31,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).